Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
Public ClinicalTrials.gov record NCT00139841. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Phase III Study to Investigate the Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent Non-Hodgkin's lymphoma and have relapsed within a defined timeframe after taking rituximab (Rituxan®). Treanda will be given via 60-minute intravenous infusion on days 1 and 2 of every 21-day treatment cycle. Patients will be treated for 6 cycles unless they develop progressive disease or unacceptable toxicity. Those who continue to receive clinical benefit at end of 6 cycles may receive an additional 2 cycles. Following the end of treatment, patients will be followed for up to 2 years until disease progression or start of another anti-cancer therapy.
Study identification
- NCT ID
- NCT00139841
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2005 (Type not available)
- Primary completion
- Jul 2007 (Actual)
- Completion
- Oct 2009 (Actual)
- Last update posted
- May 9, 2014
2005 – 2009
United States locations
- U.S. sites
- 32
- U.S. states
- 22
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35233 | — |
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Alta Bates Comprehensive Cancer Center | Berkeley | California | 94704 | — |
| Tower Hematology and Oncology Medical Group | Beverly Hills | California | 90211 | — |
| Moores UCSD Cancer Center | La Jolla | California | 92093 | — |
| USC/Norris Cancer Hospital | Los Angeles | California | 90033 | — |
| Comprehensive Cancer Center - Desert Regional Medical Center | Palm Springs | California | 92662 | — |
| Stanford University Division of Oncology | Stanford | California | 94305 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80010 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06520 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Indiana Oncology Hematology Consultants, A Division of AHN | Indianapolis | Indiana | 46202 | — |
| Markey Cancer Center, University of Kentucky Medical Center | Lexington | Kentucky | 40536 | — |
| LSU Health Sciences Center, Feist Weiller Cancer Center | Shreveport | Louisiana | 71130 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Michigan Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63110 | — |
| Nevada Cancer Institute | Las Vegas | Nevada | 89135 | — |
| University of New Mexico Cancer Research and Treatment Center | Albuquerque | New Mexico | 87131 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Weill Cornell Cancer Care Center | New York | New York | 10021 | — |
| Interlakes Foundation, Inc. | Rochester | New York | 14623 | — |
| University of Rochester Medical Center, James P. Wilmot Cancer Center | Rochester | New York | 14642 | — |
| Duke University School of Medicine | Durham | North Carolina | 27710 | — |
| The Cleveland Clinic Foundation Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
| The West Clinic/ACORN | Memphis | Tennessee | 38138 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Arlington Cancer Center | Arlington | Texas | 76012 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22908 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00139841, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 9, 2014 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00139841 live on ClinicalTrials.gov.